Blood screening is a medical test that is accomplished on blood samples for diagnosis of various diseases such as syphilis, hepatitis, AIDS and other clinical conditions such as pregnancy. According to Marketstack, the Global Blood Screening Market is expected to grow considerably during the forecasted period. Factors such as the reagents & kits used to detect the presence of disease-associated antigens in a blood sample are expected to drive the Blood Screening Market in the forecasted period. Further, there is an increase in blood donations and blood transfusions-related screenings are expected to drive the Blood Screening Market in the forecasted period. Furthermore, the increasing awareness about transfusion-transmitted diseases is expected to fuel the Global Blood Screening Market in the forecasted period. However, the high costs involved in blood sampling, the need for laws, regulations, and guidelines relating to blood transfusion-related activities in some countries, and the development of alternative technologies to return blood screening might hinder the growth of the Blood Screening Market.

The reagents and kits fragment is estimated to grow significantly during the forecasted period. The reagents and kits segment is one of the vital segments used in the laboratory testing process to screen donated blood for infectious diseases and ensure its safety for transfusion. The reagent market segment of the analysis includes chemical, biological, or immunological reagents, solutions, or products that the manufacturer intends to use in the blood screening process. In addition, reagents are cost-effective for customers and give the vendors a high return on investment. Reagents, a recurring expense, are extensively used in immunoassays and molecular tests. Factors such as surged blood donations and transfusion-related screenings, as well as the rising prevalence of infectious diseases, are propelling the growth of this segment. These kits use polymerase chain reaction (PCR) in clinical chemistry dia, bites, test strips, in vitro and molecular diagnostics, and the detection of illicit drugs. Reagents and kits are also utilized privately or at the Point of Care (POC) for glucose strips, DNA lineage analysis, and at-home pregnancy tests. Reagents can be substances or compounds utilized in laboratory tests to create a chemical reaction with specific compositions in a sample, such as blood. There is a growing adoption of reagents in blood screening to diagnose the presence of antigens, antibodies, or other markers associated with infectious diseases. This fragment is a vital part of the testing process and is selected depending on its sensitivity, specificity, and reliability in detecting specific pathogens. Hence, such factors are anticipated to fuel the growth of this fragment, which in turn will propel the market development in the forecasted period.

North America has the largest share and continues to dominate the blood screening market. The factors responsible for the large percentage of North Americans in this market are the increasing prevalence of infectious diseases, rising awareness of blood donations, and the growing healthcare system that is highly developed in the US and Canada. The blood screening process mainly consists of testing donated blood for various pathogens and health conditions before it is utilized for medical treatments. The Advancements in medical technology and increased awareness of regulatory requirements, blood safety, and healthcare needs are fuelling the demand for blood screening in North America. Blood banks must ensure that donated blood is safe from infectious diseases, including hepatitis B and C, HIV, and other pathogens. The primary purpose of screening is that it helps to recognize and discard potentially contaminated units. There is a rising need for blood for different medical procedures, such as trauma care, cancer treatments, surgeries, and more. Therefore, proper screening is essential to reducing the risk of transfusion complications. There is a rising demand for blood screening to stop the spread of these diseases through transfusions owing to outbreaks of infectious diseases or emerging health threats. Demand for blood screening in this region is driven by the surging number of organ transplant operations and the prevalence of transfusion-transmissible illnesses such as hepatitis B, hepatitis C, HIV, and syphilis across the globe. In addition, the risk of transmitting serious diseases such as hepatitis and HIV through contaminated blood, as well as determined blood shortages, has highlighted the need for accessible and safe blood across the globe. As a result, WHO advises that all blood donations be checked for pathogens before use, encouraging blood banks to implement blood screening. Furthermore, blood banks utilize blood screening more frequently since it can help with blood grouping, compatibility tests, and systems that process blood into blood products to fulfil medical demands. Many blood banks use blood screening technology effectively to minimize transfusion-related risks, reduce unnecessary blood transfusions, and improve patient blood management, which is predicted to drive revenue growth in this segment.

The market key players are Abbott Laboratories, Danaher Corporation (Beckman Coulter), Becton Dickinson and Company, Bio-Rad Laboratories, Inc., and Hoffman-La Roche Ltd.

In May 2023, Bio-Rad Laboratories, Inc. announced the launch of the IH-500TM NEXT System, a fully automated system for ID cards. The IH-500 NEXT System is used with Bio-Rad's ID cards, offering a broad portfolio for routine testing (type and screen) and specialized testing, including single antigen determination and newborn screening.

In November 2023, Diasorin announced it would develop the first fully automated diagnostic test for hepatitis delta virus (HDV) on the U.S. Diasorin LIAISON XL immunoassay system.

Our Global Blood Screening Market report provides deep insight into the current and future state of the market across various regions. Also, the study comprehensively analyzes the Blood Screening market by segments based on the Product (Instruments, Kits and Reagents), Technology (NAT Technology, Immunoassays), End User (Blood Banks, Hospitals), and Geography (Asia Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers & includes emerging market trends, market developments, market opportunities, market size, market analysis, market dynamics, and challenges in the industry. This report also covers extensively researched competitive landscape sections with profiles of prominent companies, including their market share and projects.